Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > TOP STORIES
TOP STORIES
-
ACADEMIA RA Treatment Guidelines to Reflect Patients’ Values and Economic Considerations as Well as Evidence
April 24, 2013
-
ACADEMIA New COPD Guidelines Recommend LAMA, LABA on Equal Footing
April 23, 2013
-
BUSINESS Pfizer-Mylan Pair’s Japan Generic Share at 2.8%, Aspire for Bigger Slice of Market
April 22, 2013
-
BUSINESS Tug-of-War over “Conflicts of Interest” (2): “Diovan Scandal” Brings Renewed Attention to COI
April 19, 2013
-
BUSINESS Novo Nordisk Ups Efforts in Basal Insulin Market, Pits Tresiba against Lantus
April 18, 2013
-
ORGANIZATION Tug-of-War over “Conflicts of Interest” (1): Drug Makers, Doctors Remain Divided
April 18, 2013
-
BUSINESS Teijin Pharma Hopes to Derive 50%-Plus of Sales from New Drugs by around 2016: Pres. Uno
April 17, 2013
-
REGULATORY Growing Concern Over Return to Brand Names for Generics with Advent of Generic Versions of Combination Drugs
April 16, 2013
-
REGULATORY Supreme Court Rejects Damage Claims in Iressa Suits; Govt, AZ Win 8-Year Battle
April 15, 2013
-
BUSINESS 11 Drug Makers to Increase, 11 to Decrease Hiring Next Year; Mid-Sized Companies Most Optimistic on Hiring
April 15, 2013
-
REGULATORY Generic Roadmap: CSIMC Bill Payer Rep Says New 60% Target Could “Decelerate” Shift
April 12, 2013
-
BUSINESS Eisai Announces Organizational Reforms; “We Won’t Allow Generics to Overwhelm AD Market”: President Naito
April 12, 2013
-
BUSINESS Shire Enters Japan Full Force, Six Products to Be Launched in Five Years
April 11, 2013
-
BUSINESS Amgen Plans New Product Debuts in Japan by 2016, Pins Hopes on Hyperlipidemia Drug
April 10, 2013
-
BUSINESS Rubella Epidemic Triggers Vaccine Shipment Adjustments at Drug Makers
April 9, 2013
-
REGULATORY MHLW Unveils Generic Roadmap, Aims for 60%-Share by FY2017
April 8, 2013
-
BUSINESS Takeda to Successively File 2 New Diabetes Drugs in Japan
April 5, 2013
-
BUSINESS Protected Drugs Represent More than 50% of Bayer Yakuhin Sales in 2012, Over 60% Eyed by 2014: Pres. Brunn
April 4, 2013
-
BUSINESS Presidents of Pharmaceutical Companies Stress Globalization, Compliance in Welcoming Ceremonies for New Employees
April 4, 2013
-
BUSINESS Janssen Poised to Keep Up Double-Digit Growth, Focus on 5 Therapeutic Areas: Japan Pres. Goodwin
April 3, 2013
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…